BirkholzK., HombachA., KrugC., ReuterS., KershawM., KämpgenE., SchulerG., AbkenH., SchaftN., DörrieJ.2009. Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer. Gene Ther., 16:596–604.
2.
BrentjensR., YehR., BernalY., RiviereI., SadelainM.2010a. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: Case report of an unforeseen adverse event in a phase I clinical trial. Mol. Ther., 18:666–668.
3.
BrentjensR., RiviereI., FrattiniM., WangY., TaylorC., OlszewskaM., Borquez-OjedaO., BartidoS., StefanskiJ., YehR., SadelainM.2010b. Marked regression of adenopathy following infusion of autologous T cells genetically targeted to the CD19 antigen in a patient with bulky CLL. Abstract presented at the 13th Annual Meeting of the American Society of Gene and Cell Therapy, May 17–22, 2010, Washington, D.C..
4.
BrentjensR.J., SantosE., NikhaminY., YehR., MatsushitaM., La PerleK., Quintás-CardamaA., LarsonS.M., SadelainM.2007. Genetically targeted T cell eradicate systemic acute lymphoblastic leukemia xenografts. Clin. Cancer Res., 13:5426–5435.
5.
CarpenitoC., MiloneM.C., HassanR., SimonetJ.C., LakhalM., SuhoskiM.M., Varela-RohenaA., HainesK.M., HeitjanD.F., AlbeldaS.M., CarrollR.G., RileyJ.L., PastanI., JuneC.H.2009. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl. Acad. Sci. U.S.A., 106:3360–3365.
6.
ChmielewskiM., HombachA., HeuserC., AdamsG.P., AbkenH.2004. T cell activation by antibody-like immunoreceptors: Increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J. Immunol., 173:7647–7653.
CooperL.J., Al-KadhimiZ., SerranoL.M., PfeifferT., OlivaresS., CastroA., ChangW.C., GonzalezS., SmithD., FormanS.J., JensenM.C.2005. Enhanced anti-lymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood, 105:1622–1631.
9.
de WitteM.A., JorritsmaA., SwartE., StraathofK.C., de PunderK., HaanenJ.B., RooneyC.M., SchumacherT.N.2008. An inducible caspase-9 safety switch can halt cell therapy-induced autoimmune disease. J. Immunol., 180:6365–6373.
10.
DudleyM.E., WunderlichJ.R., YangJ.C., SherryR.M., TopalianS.L., RestifoN.P., RoyalR.E., KammulaU., WhiteD.E., MavroukakisS.A., RogersL.J., GraciaG.J., JonesS.A., MangiameliD.P., PelletierM.M., Gea-BanaclocheJ., RobinsonM.R., BermanD.M., FilieA.C., AbatiA., RosenbergS.A.2005. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol., 23:2346–2357.
11.
DudleyM.E., YangJ.C., SherryR., HughesM.S., RoyalR., KammulaU., RobbinsP.F., HuangJ., CitrinD.E., LeitmanS.F., WunderlichJ., RestifoN.P., ThomasianA., DowneyS.G., SmithF.O., KlapperJ., MortonK., LaurencotC., WhiteD.E., RosenbergS.A.2008. Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol., 26:5233–5239.
12.
EshharZ.2008. The T-body approach: Redirecting T cells with antibody specificity. Handb. Exp. Pharmacol., 181:329–342.
13.
HombachA., HombachA.A., AbkenH.2010. Adoptive immunotherapy with genetically engineered T cells: Modification of the IgG1 Fc “spacer” domain in the extracellular moiety of chimeric antigen receptors avoids “off-target” activation and unintended initiation of an innate immune response. Gene Ther., 2010Jun17[Epub ahead of print]doi:10.1038/gt.2010.91.
14.
HoyosV., SavoldoB., QuintarelliC., MahendravadaA., ZhangM., VeraJ., HeslopH.E., RooneyC.M., BrennerM.K., DottiG.2010. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia, 24:1160–1170.
15.
JohnsonL.A., MorganR.A., DudleyM.E., CassardL., YangJ.C., HughesM.S., KammulaU.S., RoyalR.E., SherryR.M., WunderlichJ.R., LeeC.C., RestifoN.P., SchwarzS.L., CogdillA.P., BishopR.J., KimH., BrewerC.C., RudyS.F., VanwaesC., DavisJ.L., MathurA., RipleyR.T., NathanD.A., LaurencotC.M., RosenbergS.A.2009. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood, 114:535–546.
16.
KershawM.H., WestwoodJ.A., ParkerL.L., WangG., EshharZ., MavroukakisS.A., WhiteD.E., WunderlichJ.R., CanevariS., Rogers-FreezerL., ChenC.C., YangJ.C., RosenbergS.A., HwuP.2006. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res., 12:6106–6115.
17.
KiebackE., CharoJ., SommermeyerD., BlankensteinT., UckertW.2008. A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer. Proc. Natl. Acad. Sci. U.S.A., 105:623–628.
18.
LamersC.H., SleijferS., VultoA.G., KruitW.H., KliffenM., DebetsR., GratamaJ.W., StoterG., OosterwijkE.2006. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: First clinical experience. J. Clin. Oncol., 24:e20–e22.
19.
MorganR.A., YangJ.C., KitanoM., DudleyM.E., LaurencotC.M., RosenbergS.A.2010. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther., 18:843–851.
20.
PuleM.A., SavoldoB., MyersG.D., RossigC., RussellH.V., DottiG., HulsM.H., LiuE., GeeA.P., MeiZ., YvonE., WeissH.L., LiuH., RooneyC.M., HeslopH.E., BrennerM.K.2008. Virus-specific T cells engineered to coexpress tumor-specific receptors: Persistence and antitumor activity in individuals with neuroblastoma. Nat. Med., 14:1264–1270.
21.
SuntharalingamG., PerryM.R., WardS., BrettS.J., Castello-CortesA., BrunnerM.D., PanoskaltsisN.2006. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med., 355:1018–1028.
22.
TeyS.K., DottiG., RooneyC.M., HeslopH.E., BrennerM.K.2007. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol. Blood Marrow Transplant., 13:913–924.
23.
TillB.G., JensenM.C., WangJ., ChenE.Y., WoodB.L., GreismanH.A., QianX., JamesS.E., RaubitschekA., FormanS.J., GopalA.K., PagelJ.M., LindgrenC.G., GreenbergP.D., RiddellS.R., PressO.W.2008. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood, 112:2261–2271.
24.
UckertW., KammertönsT., HaackK., QinZ., GebertJ., SchendelD.J., BlankensteinT.1998. Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo. Hum. Gene Ther., 9:855–865.
25.
VeraJ.F., BrennerM.K., DottiG.2009. Immunotherapy of human cancers using gene modified T lymphocytes. Curr. Gene Ther., 9:396–408.
26.
ZhaoY., WangQ.J., YangS., KochenderferJ.N., ZhengZ., ZhongX., SadelainM., EshharZ., RosenbergS.A., MorganR.A.2009. A Herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J. Immunol., 183:5563–5574.
